ContraFect Corporation Announces Third Quarter 2014 Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ContraFect Corporation Announces Third Quarter 2014 Results

YONKERS, NY--(Marketwired - Nov 14, 2014) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014. For the three month period ended September 30, 2014, the Company posted a net loss of $16.4 million. Cash and cash equivalents totaled $31.3 million at the end of the quarter.

"Throughout the quarter we have continued our mission to address treatments for life-threatening, drug-resistant infections; one of the healthcare community's major unmet needs," said Julia P. Gregory, chief executive officer of ContraFect. "We have continued to advance the development of our lead program, CF-301, which is a potential first-in-class molecule to address serious, life-threatening infections in the hospital, including those caused by the drug-resistant MRSA superbug. We plan to resubmit our IND for CF-301 by the end of the year. Our CF-404 program, which is a universal treatment for life-threatening influenza, has also made great strides and we are currently preparing to conduct IND enabling studies with that compound."

Key Highlights:

  • In August 2014, ContraFect completed a successful initial public offering, raising $41.3 million. The Company's common stock is trading under the symbol "CFRX" and the two publicly traded warrants originally part of the unit offering are traded under the symbols "CFRXW" and "CFRXZ."

  • ContraFect was invited to give an oral presentation of our data on CF-301 on September 9, 2014 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The presentation, titled, "Efficacy of Single-Dose Lysin CF-301 in Combination with Vancomycin (VAN) or Daptomycin (DAP) in Experimental Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA)," was presented by Michael Wittekind, Ph.D., chief scientific officer of ContraFect. The data supported ContraFect's new alternative approach to treating Staph bacteremia, demonstrating the powerful combination of CF-301 and standard-of-care antibiotics in a well-established model of infectious endocarditis.

  • In September 2014, ContraFect announced that CF-404, its universal influenza treatment, received a $3.3 million, 3.5 year Advanced Technology Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund its pre-clinical development.

  • Shortly after the end of the quarter, ContraFect entered into a collaborative research agreement with the National Institute for Viral Disease Control and Prevention, China CDC ("IVDC") to advance research and development of CF-404, its universal influenza treatment.

Financial Results:

Operating expenses for the quarter ended September 30, 2014 were $4.6 million, with $2.4 million attributable to research and development. This compares to operating expenses of $3.6 million and research and development expenses of $2.1 million for the same period in 2013. The Company incurred a net loss for the quarter ended September 30, 2014 of $16.4 million compared to a net loss of $4.4 million in the prior year period.

For the nine month period ended September 30, 2014, operating expenses were $12.1 million, with $6.5 million attributable to research and development. This compares to operating expenses of $11.9 million and research and development expenses of $6.6 million for the same period in 2013. The Company incurred a net loss for the nine months ended September 30, 2014 of $25.4 million compared to a net loss of $12.7 million in the prior year period.

The conversion of all of the Company's notes into common stock on the closing of the IPO resulted in substantially all of the $11.8 million non-cash total other expenses in the quarter which increased our net loss for both the three and nine month periods ended September 30, 2014. Our operating expenses and continued investment in research and development demonstrate how we are deploying our resources. These non-recurring, non-cash charges are not indicative of future costs.

We expect that we will conclude the year with cash of approximately $23-$25 million and full year operating expenses of approximately $18-$19 million.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Specific forward-looking statements in this release include statements regarding our expected timetable for submitting our IND for CF-301, our expectations regarding our full year operating expenses and expected cash balance at the end of the year. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

(Tables to Follow)

   
CONTRAFECT CORPORATION  
Condensed Balance Sheets  
   
    September 30,
2014
  December 31,
2013
 
    (unaudited)   (audited)  
Assets              
Current assets:              
  Cash and cash equivalents   $ 31,320,237   $ 4,145,270  
  Prepaid expenses and other current assets     417,143     198,410  
Total current assets     31,737,380     4,343,680  
Long-term assets     2,464,105     5,340,155  
Total assets   $ 34,201,485   $ 9,683,835  
Liabilities and stockholders' deficit              
Current liabilities   $ 4,228,863   $ 7,116,846  
Convertible notes payable and other long-term liabilities     403,696     15,585,162  
Total liabilities     4,692,559     22,702,008  
               
Total stockholders' equity (deficit)     29,508,926     (52,910,500 )
Total liabilities, convertible preferred stock, and stockholders' equity (deficit)   $ 34,201,485   $ 9,683,835  
               
               
               
CONTRAFECT CORPORATION  
Unaudited Statements of Operations  
   
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2014     2013     2014     2013  
Operating expenses:                                
  Research and development   $ 2,363,957     $ 2,108,397     $ 6,545,496     $ 6,601,105  
  General and administrative     2,274,569       1,465,708       5,561,432       5,249,485  
Total operating expenses     4,638,526       3,574,105       12,106,928       11,859,590  
Loss from operations     (4,638,526 )     (3,574,105 )     (12,106,928 )     (11,859,590 )
Other income (expense)                                
  Interest expense, net     (11,067,209 )     (784,075 )     (12,414,240 )     (838,776 )
  Refundable state tax credits     --       --       424,649       --  
  Change in fair value of warrant and embedded derivative liabilities     (691,943 )     --       (1,315,894 )     --  
Total other income (expense)     (11,759,152 )     (784,075 )     (13,305,485 )     (838,776 )
  Net loss     (16,397,678 )     (4,358,180 )     (25,412,413 )     (12,689,366 )
Preferred stock dividend in-kind     --       --       (4,468,452 )     --  
  Net loss attributable to common stockholders   $ (16,397,678 )   $ (4,358,180 )   $ (29,880,865 )   $ (12,689,366 )
Per share information:                                
  Net loss per share of common stock, basic and diluted*   $ (1.22 )   $ (4.31 )   $ (5.76 )   $ (12.54 )
  Basic and diluted weighted average shares outstanding*     13,403,595       1,011,997       5,187,920       1,011,670  
                                 
  *Basic and diluted net loss per share attributable to common stockholders and weighted average shares outstanding were impacted by the conversion of all the Company's outstanding convertible preferred stock and convertible notes payable on the closing of the Company's initial public offering on August 1, 2014.
   

Contact:

Barry Kappel, Ph.D., MBA
SVP Business Development
Tel: 914-207-2300
E-Mail: Email Contact
or visit: www.contrafect.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 82

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 58

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 0

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 35

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 108

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading

Top 5 Most Recently Viewed Articles

European Wax Center's Inducement Grants for New Executives

Updated Category News Views 140

Overview of Inducement Grants European Wax Center, Inc. (NASDAQ: EWCZ), known as a leading provider of out-of-home waxing services across the United States, has recently made headlines with its strategic inducement grants. This move comes in light of the recent appointments of key executives, aiming to bolster the company's leadership and operational capabilities....

Continue Reading
Enhancing AI Security: Check Point and Microsoft Partnership

Updated Category News Views 283

Enhancing AI Security Through Strategic Collaboration Check Point Software Technologies Ltd. (NASDAQ: CHKP), a renowned global leader in cyber security solutions, has embarked on an exciting partnership with Microsoft. This collaboration aims to inject enterprise-grade AI security into the Microsoft Copilot Studio, ensuring that organizations can innovate safely and...

Continue Reading
TransMontaigne Partners Strengthen Credit Facility with Extension

Updated Category News Views 238

TransMontaigne Partners LLC Enhances Credit Facility Terms TransMontaigne Partners LLC has recently announced a significant development in its financial strategy. The company has officially closed Amendment No. 4 to its existing Credit Agreement, which illustrates its commitment to optimizing financial operations and enhancing financial stability. Understanding the...

Continue Reading
Red Cross Issues Urgent Call for Blood Donations Beyond Holidays

Updated Category News Views 119

Urgent Appeal for Blood Donations Post-Holiday Season The American Red Cross is currently confronting the threat of a significant blood shortage. As the busy holiday season comes to a close, blood donation rates have plummeted. Unfortunately, the rate at which blood products are being distributed now exceeds the number of donations received, raising concerns about the...

Continue Reading
Weight Loss Drugs Linked to Genetic Hair Loss in Men

Updated Category News Views 34

When weight loss turns hairy, it's not just an old wives' tale. We have some solid evidence from those eggheads at NYU Langone Health, who unearthed this hairy connection between popular weight loss drugs and the glinting domes of the genetically predisposed. Understanding the Hair-Drug Connection The name Ozempic might sound familiar, and not just because it's been...

Continue Reading